Stocks
Guggenheim Raises Merck Price Target to $170
Guggenheim has raised its price target for Merck (no ticker mentioned) to $170 from $146. This move reflects an increase of nearly 17% in the expected value of the company's shares.
No specific reason is given in the source for this upward revision, but it suggests that analysts at Guggenheim believe Merck will perform better than previously anticipated.
The TipRanks Smart Score performance is based on backtested results, which are not an indicator of future actual results. The disclaimer notes that past returns may have under- or over-compensated for the impact of certain market factors, such as lack of liquidity.